EUS-guided ethanol ablation for small pancreatic neuroendocrine neoplasm

Affiliations

Editorial

Reiko Ashida. Dig Endosc. 2020 Mar.

. 2020 Mar;32(3):326-327.

doi: 10.1111/den.13646.

¹ Departments of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

No abstract available

Comment on

Efficacy and safety of scheduled early endoscopic ultrasonography-guided ethanol reinjection for patients with pancreatic neuroendocrine tumors: Prospective pilot study.
Matsumoto K, Kato H, Kawano S, Fujiwara H, Nishida K, Harada R, Fujii M, Yoshida R, Umeda Y, Hinotsu S, Yagi T, Okada H. Matsumoto K, et al. Dig Endosc. 2020 Mar;32(3):425-430. doi: 10.1111/den.13552. Epub 2019 Nov 6. Dig Endosc. 2020. PMID: 31580507 Clinical Trial.

1. Scoazec JY, Couvelard A, Reseau T. Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann. Pathol. 2017; 37(6): 444-56.
1. Scott AT, Howe JR. Evaluation and management of neuroendocrine tumors of the pancreas. Surg. Clin. North Am. 2019; 99(4): 793-814.
1. Jurgensen C, Schuppan D, Neser F et al. EUS-guided alcohol ablation of an insulinoma. Gastrointest. Endosc. 2006; 63(7): 1059-62.
1. Choi JH, Park DH, Kim MH et al. Outcomes after endoscopic ultrasound-guided ethanol-lipiodol ablation of small pancreatic neuroendocrine tumors. Dig. Endosc. 2018; 30(5): 652-8.
1. Deprez PH, Claessens A, Borbath I et al. Successful endoscopic ultrasound-guided ethanol ablation of a sporadic insulinoma. Acta Gastroenterol. Belg. 2008; 71(3): 333-7.